TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04626219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Imaging - Magnetic Resonance Imaging (MRI) scan of their heads

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
Study: NCT00185614

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: 200 centigray (cGy) total body irradiation delivered on Day 0
Study: NCT04626219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fast
Description: hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
Study: NCT00185614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP)
Description: Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
Study: NCT04626219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: regulated meals
Description: standardized diet from noon until 9 a.m. the next day
Study: NCT02096380

Intervention type: DRUG
Intervention: One cycle TPF induction chemotherapy for NPC
Description: One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2.

Intervention type: DRUG
Intervention: Three cycles TPF induction chemotherapy for NPC
Description: Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2.
Study: NCT04392362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: A vial of adenosine with 6mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: A vial of adenosine with 6mg
Study: NCT00059280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg qow or 40mg/kg qow
Study: NCT00432991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine [Synonyms: Ephedra, Ephedrinum]
Description: 25 mg, IM (in the muscle), one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: 0.5 mL, IM (in the muscle), one time
Study: NCT04445467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir
Description: Favipiravir
Study: NCT02225795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Immuno-ablative regimen for HSCT:~Day Treatment~* 6 r-ATG 2 mg/kg~* 5 r-ATG3 2 mg/kg~* 4 r-ATG3 2 mg/kg~* 3 Cyclophosphamide with Mesna~* 2 Cyclophosphamide with Mesna~* 1 REST 0 PBSC infusion~  * 3 Cyclophosphamide with Mesna~ * 4 Cyclophosphamide with Mesna~ * 6 Start GCSF
Study: NCT00949065

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulins
Description: 0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: intravenous immunoglobulins
Description: 0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
Study: NCT02918630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
Study: NCT01807741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Available in 5 and 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03239054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Information will be given as part of standard care
Study: NCT03166358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: 8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
Study: NCT02166593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin40mg/Fenofibrate160mg
Description: Pravafenix(Pravastatin40mg/Fenofibrate160mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin40mg/Fenofibrate160mg
Description: Pravafenix(Pravastatin40mg/Fenofibrate160mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Sodium 10mg
Description: Lipitor 10mg(Atorvastatin Sodium)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Sodium 10mg
Description: Lipitor 10mg(Atorvastatin Sodium)
Study: NCT02660424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Study: NCT05855278

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
Study: NCT01755754

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Silicone Elastomer Vaginal Ring
Description: Silicone Elastomer Vaginal Ring

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Silicone Elastomer Vaginal Ring
Description: Silicone Elastomer Vaginal Ring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Female Condom
Description: Female condom
Study: NCT01028560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergen extracts (subcutaneous injections)
Description: Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: standard of care asthma and allergy treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: standard of care asthma and allergy treatment
Study: NCT01894646

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Imaging
Study: NCT02660424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01894646

Intervention type: RADIATION
Group type: OTHER
Intervention: Positron Emission Tomography (PET) Imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Imaging
Study: NCT00941395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study: NCT04505787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esflurbiprofen hydrogel patch 165 mg (EFHP)
Description: patch application with PK blood sampling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Froben 100 mg comprimidos revestidos
Description: tablet administration with PK blood sampling
Study: NCT00814736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK369,003
Description: oral tablet, once a day
Study: NCT02660424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00814736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: single oral dose on day 14 or day 17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil matching placebo
Description: single oral dose on day 14 or day 17
Study: NCT04922879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized lung rehabilitation
Description: Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
Study: NCT04332770

Intervention type: OTHER
Intervention: levothyroxine withdrawal
Description: All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
Study: NCT01772771

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, saliva/buccal swab samples

Intervention type: OTHER
Intervention: Genetic Testing
Description: Correlative studies

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records
Study: NCT03743584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted temperature management
Description: Target temperature management at 33°C

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care, early treatment of fever
Description: Standard of care with early treatment of fever
Study: NCT01793571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: 2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: 2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
Study: NCT01773889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin Diftitox/SC Pegylated IFNα-2a
Study: NCT03997591

Intervention type: OTHER
Intervention: Ready2E.A.T. PROGRAM
Description: Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy.

Intervention type: OTHER
Intervention: Ready2E.A.T. PROGRAM
Description: Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy.
Study: NCT00416637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Study: NCT03397797

Intervention type: DRUG
Intervention: Rocuronium
Description: In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
Study: NCT02027688

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: q6 hour oral feeding schedule
Description: The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: q3 hour oral feeding schedule
Description: The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
Study: NCT00611455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: 1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
Study: NCT02676310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Study: NCT04273295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
Study: NCT02520193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized early mobilization in ICU
Study: NCT01336088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX48621
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT03330496

Intervention type: OTHER
Intervention: Pain Measurement
Description: Measurement of infant responses (behavioral and physiological) during a painful procedure.

Intervention type: OTHER
Intervention: Pain Measurement
Description: Measurement of infant responses (behavioral and physiological) during a painful procedure.

Intervention type: OTHER
Intervention: Pain Measurement
Description: Measurement of infant responses (behavioral and physiological) during a painful procedure.

Intervention type: OTHER
Intervention: Pain Measurement
Description: Measurement of infant responses (behavioral and physiological) during a painful procedure.
Study: NCT03013036

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasonography

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasonography

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasonography

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane

Intervention type: DRUG
Group type: OTHER
Intervention: intravenous midazolam

Intervention type: DRUG
Group type: OTHER
Intervention: intravenous midazolam

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol

Intervention type: DRUG
Group type: OTHER
Intervention: fentanyl and rocuronium

Intervention type: DRUG
Group type: OTHER
Intervention: fentanyl and rocuronium

Intervention type: DRUG
Group type: OTHER
Intervention: fentanyl and rocuronium
Study: NCT03570515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
Study: NCT00951535

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: quality-of-life assessment
Study: NCT03570515

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational film
Description: Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
Study: NCT00562198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entacapone and carbidopa
Description: Entacapone 200mg carbidopa 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet 200mg/50mg
Description: Sinemet 200mg/50mg once
Study: NCT02241031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPs
Description: MPs are generated from cord blood using a combination of cytokines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thrombopoietin (TPO) and interleukin-11
Description: Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
Study: NCT00151073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT00000437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Tablet and Nicotine Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Tablet and Placebo Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet and Nicotine Patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet and Placebo Patch
Study: NCT00951535

Intervention type: RADIATION
Group type: OTHER
Intervention: image-guided radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy treatment planning/simulation
Study: NCT03387462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: Open label daily emtricitabine/tenofovir disoproxil oral tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT Diary mobile app
Description: DOT Diary mobile application for tracking medication adherence and sexual activities.
Study: NCT03062787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)
Description: Intra-articular injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc® (Sodium hyaluronate)
Description: Intra-articular injection
Study: NCT01424020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
Study: NCT03694236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated.
Study: NCT00629057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-PRO
Description: 1x10e8 TCID50 q 4 wks x 6
Study: NCT02040012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZP-531

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01744626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Description: Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
Study: NCT02471677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elonva
Description: corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Puregon
Description: follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
Study: NCT04238182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wet cupping
Description: This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry cupping
Description: The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
Study: NCT00458705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide